Drugs / CD20/CD22 dual Targeted CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04283006 | May 2018 → May 2023 overdue | hematopoietic and lymphoid cell neoplasm, lymphoid hemopathy | He Huang | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD20/CD22 dual Targeted CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04283006 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy” NCT04283006 ↗ |
| Route | Intravenous | “Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion” NCT04283006 ↗ |
| Target | CD20 | “CD20 / CD22 dual-target CAR T-cells” NCT04283006 ↗ |
| Target | CD22 | “CD20 / CD22 dual-target CAR T-cells” NCT04283006 ↗ |